APPENDIX 34: EXCLUDED STUDIES TABLES

STUDY ID	REASON FOR EXCLUSION
Studies of adults	
AHLFORS1981	Included participants with bipolar and unipolar depressive illness. Disaggregated data was not available
AHUJA2011	Results not available
ALTAMURA2003	Comparison not eligible
ALTAMURA2004	Maintenance trial with a follow-up of less than one year
AMSTERDAM2005b	Maintenance trial with a follow-up of less than one year
AMSTERDAM2008	Open label
AMSTERDAM2009	Open label
AMSTERDAM2010	Maintenance trial with a follow-up of less than one year
ASTRAZENECA2012	Open label
ASTRAZENECA2012	Open label
BAASTRUP1970	Included participants until the result was statistically significant. Participants did not give consent and some were not aware that their lithium tablets had been exchanged for placebo. Only 60% had bipolar disorder and disaggregated data was not available
BENEDETTI1997	Only 5 participants in each group
BERK2008	Drug not indicated for mental health and not in common use
BERK2012	Drug not indicated for mental health and not in common use
BOSE2012	Results not available
BOWDEN2010	Maintenance trial with a follow-up of less than one year
BOWDEN2012	Maintenance trial with a follow-up of less than one year
BRISTOLMYERSSQUIBB2011	Results not available
BURDICK2012	Maintenance trial with a follow-up of less than one year
CALABRESE2000	Maintenance trial with a follow-up of less than one year
CAMURI2013	No sham control group
CHENGAPPA2000	Drug not indicated for mental health and not in common use
COLOMBO2000	Only efficacy outcomes are mood visual analogue scales with no suggestion of validity
COSTA2011	The allocation of participants was not random
CUNDALL1972	Maintenance trial with a follow-up of less than one year
DASHTBOZORGI2009	Trial of family psychoeducation in Iran. The GDG agreed this was not relevant to the UK
DENICOFF2005	Drug not indicated for mental health and not in common use
DIAZGRANDOS2010	Drug not indicated for mental health and not in common use
DOLBERG2002	No sham control group
ELMALLAKH2009	Maintenance trial with a follow-up of less than one year
ESPARON1986	Drug not indicated for mental health and not in common use
FIEVE1968	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
FOREST2010	Data was not provided
FOREST2012	Results not available

STUDY ID	REASON FOR EXCLUSION
FRANGOU2006	Does not meet inclusion criteria for acute depression
FURLEY2013	Drug not indicated for mental health and not in common use
GAO2008	Authors did not provide data
GINDRE2009	Protocol of a trial; authors have not confirmed whether trial has been completed
GOLDBERG2004	Did not include a sufficient number of participants
GRISARU1998	No sham control group
GSK2012	Maintenance trial with a follow-up of less than one year
JACKSON2008	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
JONES2013	Study protocol
KECK2006a	Maintenance trial with a follow-up of less than one year
KESSELL1975	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
KNESEVICH2009	Results not available
KULKARNI2006	Drug not indicated for mental health and not in common use
MARANGELL2006	Only 10 participants in total
MCELROY2011	Drug not indicated for mental health and not in common use
MCELROY2013	Results not available
MURPHY2012	Maintenance trial with a follow-up of less than one year
NIERENBERG2006	Open label
NIERENBERG2013	Maintenance trial with a follow-up of less than one year
NOLEN2007	Open label
NORRIS2013	Drug not indicated for mental health and not in common use
OKUMA1981	Results not available
OSHER2005	Only 6 participants in each group
PICKETT-SCHENK2008	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
PRAHARAJ2009	The allocation of participants was quasi-random
PRASKO2013	On-going trial
SCHAFFER2013	Open label
SHEEHAN2009	Treatment of 'bipolar anxiety'
SHEEHAN2013	Treatment of 'bipolar anxiety'
SINGH2013	Open label
SMITH1978	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
SOLOMON1997	Only 12 participants in total
SPEER2009	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
STAMM2011	Drug not indicated for mental health and not in common use
STARING2010	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
STOLL1999	Maintenance trial with a follow-up of less than one year

STUDY ID	REASON FOR EXCLUSION
SUPPES1999	Less than 66% of participants had a diagnosis of bipolar disorder and disaggregated data was not available.
SZUBA2005	Drug not indicated for mental health and not in common use
TAMAYO2009	Open label
TOHEN2006	Maintenance trial with a follow-up of less than one year
VITA2013	Open label
WANG2010	Open label
WATSON2012	Drug not indicated for mental health and not in common use
WOO2011	Maintenance trial with a follow-up of less than one year
YANG2009	Full report not available
YONGNING2005	Open label
YOUNG2004	Drug not indicated for mental health and not in common use
ZARATE2004	Maintenance trial with a follow-up of less than one year
ZHANG2007	Drug not indicated for mental health and not in common use
ZHUO2005	Open label
Studies of children	
FINDLING2013	Maintenance trial with a follow-up of less than one year
GELLER2012	Open label
JOSHI2013	Open label
KOWATCH2000	Open label
WOZINAK2012	Study terminated
WOZNIAK2009	The allocation of participants was quasi-random

Excluded case identification studies

STUDY ID	REASON FOR EXCLUSION
BENAZZI2003	No healthy controls (clinical sample of remitted patients with bipolar and major depressive disorder)
CASTELO2012	No structured clinical interview done; validation against primary care medical records
CHUNG2009	Instrument not in English (Chinese version of MDQ)
DAS2005	No structured clinical interview done; validation against primary care medical records
DESOUSAGURGEL2012	Instrument not in English (Portuguese version of MDQ); sample was clinical and university students
FREEMAN2012	No healthy controls (sample from academic medical centre enriched for mood disorders and community mental health centre)
FREY2012	Sample consisted only of pre- and post-partum women referred with psychiatric problems
GRAVES2007	Sample consisted only of participants subject to trauma, not generalizable to general population
HIRSCHFELD2005	Not comparable to general population; patients treated for depression attending primary care, high scorers
JON2009	Instrument not in English (Korean version of MDQ); no structured clinical interview

STUDY ID	REASON FOR EXCLUSION
KEMP2008	Not comparable to general population; adult detainees in a prison only
MEYER2011	No healthy controls (clinical sample of patients from psychiatric clinics an outpatient clinics)
MILLER2011	Three studies: study 1 did not use structured clinical interview; study 2 – participants were not administered HPS-6 as a screening instrument; study 3 – not comparable to general population as only university students and high scorers
PRETI2007	Not specific for bipolar; we wrote to the author to ask for results in bipolar subgroup but those were not available
SANCHEZMORENO2008	Instrument not in English (Spanish version of MDQ); no structured clinical interview
VIETA2007	Instrument not in English (Spanish version of MDQ); participants attended clinics (not clear where the healthy controls were selected from); no structured clinical interview
YOUNG1978	No healthy controls (participants were adult patients admitted to hospital with mania)
YOUNGSTROM2011	Conference abstract; no full text available; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
YOUNGSTROM2004	Not comparable to general population; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
YOUNGSTROM2003	Not comparable to general population; clinical sample (participants recruited from research patients seen at a division of child and adolescent psychiatry)
YOUNGSTROM2005	Not comparable to general population; clinical sample (participants recruited from a community mental health centre and outpatient academic medical centre)
ZIMMERMAN2010	Reports four studies that use a clinical sample (psychiatric outpatients): Hardoy et al., 2005; Konuk et al., 2007; Zimmerman et al., 2009 and Benazzi, 2003.

Studies that were ongoing or awaiting assessment

STUDY ID	REASON FOR EXCLUSION
AHUJA2011	Results not available
BOSE2012	Results not available
BRISTOLMYERSSQUIBB2011	Results not available
FOREST2010	Results not available
FOREST2012	Results not available
GAO2008	Authors did not provide data
GINDRE2009	Protocol of a trial; authors have not confirmed whether trial has been completed
JONES2013	Study protocol
KNESEVICH2009	Results not available
MCELROY2013	Results not available
OKUMA1981	Results not available

PRASKO2013	On-going trial
YANG2009	Full report not available

References

Ahlfors UG, Baastrup PC. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatrica Scandinavica. 1962; 64(3):226-237.

Ahuja S, Bose A, Lu K, Greenberg W, Németh G, Laszlovszky I. A Multicenter, Randomized, Double-Blind Trial to Evaluate the Effect of Cariprazine in Bipolar Depression Conference of the International Society for CNS Clinical Trials and Methodology, 3-4 Oct 2011, Amelia Island, Florida.

Altamura AC, Russo M, et al. Comparative Evaluation of Olanzapine Efficacy in the Maintenance Treatment of Bipolar Disorder. Journal of Clinical Psychopharmacology. 2004; 24(4):454-456.

Altamura AC, Salvadori D, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: Preliminary evidence from a 12-month open-label study. Journal of Affective Disorders. 2003; 76(1-3):267-271.

Amsterdam JDS. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? Journal of Affective Disorders. 2009;115:234-240.

Amsterdam JDS. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. American Journal of Psychiatry. 2010;167(7):792-800.

Amsterdam JDS. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology. 2005;20(5):257-264.

Amsterdam JDS. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode? Journal of Affective Disorders. 2009;115(1-2):234-240.

Astrazeneca. (unpublished) Effectiveness of quetiapine XR vs. sertaline in acute bipolar depression as add-on therapy to previous mood stabilizer treatment: a pilot study. [D1443L00058 /NCT00857584]. 2012a; Available from: http://clinicaltrials.gov/show/NCT00857584 [accessed 4 March 2014].

Astrazaneca. (unpublished) Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (QUALITY) [NCT00883493/D1443L00055]. 2012b; Available from:

http://clinicaltrials.gov/ct2/show/NCT00883493?term=NCT00883493&rank=1 [accessed 5 March 2014].

Baastrup PC, Poulsen JC, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet. 1970;2:326-330.

Benazzi F. Improving the Mood Disorder Questionnaire to Detect Bipolar II Disorder. Canadian Journal of Psychiatry 2003; 48(11):770-771.

Benedetti F, et al. Sleep deprivation hastens the antidepressant action of fluoxetine. European Archives of Psychiatry and Clinical Neuroscience. 1997;247(2):100-103.
Berk M, Dean OM, et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine. 2012;10:91.

Berk MC. N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder-A Double-Blind Randomized Placebo-Controlled Trial. Biological Psychiatry. 2008;64(6):468-475.

Bose A, Starace A, Wang Q, Diaz E, Goodman J, Ruth A, Németh Gy, Laszlovszky I. Cariprazine in the treatment of acute mania in bipolar disorder: A double-blind, placebo-controlled, phase III trial. 165th Annual Meeting of the American Psychiatric Association, 5-9 May 2012, Philadelphia, PA

Bowden CLV. Ziprasidone plus a mood stabilizer in subjects with bipolar i disorder: A 6-month, randomized, placebo-controlled, double-blind trial. Journal of Clinical Psychiatry. 2010; 71(2):130-137.

Bowden CLV, Singh, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatrica Scandinavica. 2012; 126(5):342-350.

Bristol Myers Squibb. A 12-week, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated with Valproate or Lithium and in Need of Further Clinical Improvement. 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00665366 [accessed 4 March 2014].

Burdick KE, Braga RJ, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: Targeting cognitive dysfunction. Journal of Clinical Psychiatry. 2012; 73(1): 103-112.

Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry. 2000; 61:841-850

Camuri G. Augmentative repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of drug-resistant depression. European Psychiatry. 2013;28 (conference abstract).

Castelo MS, et al. Screening for bipolar disorder in the primary care: a Brazilian survey." Journal of Affective Disorders. 2012; 143(1-3):118-124.

Chengappa KN, Levine J, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disorders. 2000; 2(1):47-55.

Chung KF, et al. Validation of the Mood Disorder Questionnaire in the general population in Hong Kong. Comprehensive Psychiatry. 2009; 50(5):471-476.

Colombo C, et al. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: Replication of main effects and interaction. Psychiatry Research. 2000; 95(1):43-53.

Costa RT, Cheniaux E, et al. The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study. Revista Brasileira de Psiquiatria. 2011; 33(2):144-149.

Cundall R, Brooks P, et al. A controlled evaluation of lithium prophylaxis in affective disorders. Psychological Medicine. 1972; 2(3):308-311.

Das AK, et al. Screening for bipolar disorder in a primary care practice. JAMA: the journal of the American Medical Association. 2005; 293(8): 956-963.

Dashtbozorgi, B., F. Ghadirian, et al. Effect of family psychoeducation on the level of adaptation and improvement of patients with mood disorders. [Farsi (Iranian)]. Iranian Journal of Psychiatry and Clinical Psychology. 2009; 15(2).

de Sousa Gurgel, W., et al. Brazilian Portuguese validation of Mood Disorder Questionnaire. Comprehensive Psychiatry. 2012 53(3):308-312.

Denicoff KD, Singh J, et al. Antiglucocorticoid therapy in bipolar depression with mifepristone. Bipolar Disorders. 2005; 7(S2):47.

Diazgranados N, Ibrahim L, Brutsche N, et al. A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. Arch Gen Psychiatry. 2010; 67(8); 793-802

Dolberg O, et al. Transcranial magnetic stimulation in patients with bipolar depression: A double blind, controlled study. Bipolar Disorders. 2002; 4(S1):94-95.

El-Mallakh RSS. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded,

randomized study. International Clinical Psychopharmacology. 2009; 24(3):145-149.

Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. British Journal of Psychiatry. 1986; 148:723–5.

Fieve, RR, Platman SR, et al. The use of lithium in affective disorders. I. Acute endogenous depression. The American Journal of Psychiatry. 1968; 125(4):487-491.

Findling RLK, et al. Post-Acute Effectiveness of Lithium in Pediatric Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology. 2013; 23(2):80-90

Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce positive phase III results with the investigational antipsychotic cariprazine in patients with acute mania associated with bipolar I disorder. Press Release. 8 February 2012. Available from: http://news.frx.com/press-release/product-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-ii [accessed 5 March 2014]

Forest Laboratories, Inc. Forest Laboratories, Inc. and Gedeon Richter Plc. Announce results from a phase II study of cariprazine for the treatment of bipolar depression. Press Release. 30 August 2010. Available from: http://news.frx.com/press-release/rd-news/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-phase-ii-stu-0 [accessed 5 March 2014]

Frangou SL. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. British Journal of Psychiatry. 2006; 188:46-50.

Freeman AJ, et al. Portability of a screener for pediatric bipolar disorder to a diverse setting. Psychological Assessment. 2012; 24(2):341-351.

Frey BN, et al. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. Journal of Clinical Psychiatry. 2012; 73(11):1456-1461.

Furey ML, and Zarate CA. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side. Journal of Clinical Psychiatry. 2013; 74(8):850-851.

Gao KK. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disorders. 2008; 10(8):907-915.

Geller BL. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of General Psychiatry. 2012;69(5):515-528.

Gindre CH. Changes in daily life associated with psychoeducation for bipolar disorder. Annales Medico-Psychologiques. 2009; 167(4):280-284.

Glaxosmithkline. (unpublished) An evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in patients with bipolar I disorder [SCA104779]. 2012. Available from: http://www.gsk-clinicalstudyregister.com/study/SCA104779#ps [accessed 5 March 2014].

Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry. 2004;161:564–566.

Graves RE, et al. Diagnosing bipolar disorder in trauma exposed primary care patients. Bipolar Disorders. 2007;9(4):318-323.

Grisaru N, et al. Transcranial magnetic stimulation in mania: A controlled study. American Journal of Psychiatry. 1998;155(11):1608-1610.

Hirschfeld RM, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. The Journal of the American Board of Family Practice/American Board of Family Practice. 2005;18(4):233-239.

Jackson HG, McGorry PD, Killackey E, et al. Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project. Psychological Medicine. 2008; 38(5):725–735.

Jon DI, et al. Validity and reliability of the Korean version of the Mood Disorder Questionnaire. Comprehensive Psychiatry. 2009; 50(3):286-291.

Jones S, McGrath E, Hampshire K, et al. A randomised controlled trial of time limited CBT informed psychological therapy for anxiety in bipolar disorder. BMC Psychiatry. 2013; 13:54.

Joshi G. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology. 2013;227(3): 449-458.

Keck Jr PE. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal of Clinical Psychiatry. 2006; 67(4):626-637.

Kemp DE, et al. Screening for bipolar disorder in a county jail at the time of criminal arrest." Journal of Psychiatric Research. 2008;42(9):778-786.

Kessell A, and Holt NF. A controlled study of a tetracyclic antidepressant--maprotiline (Ludiomil). Medical Journal of Australia. 1975;1(25):773-776.

Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2000;39:713-720.

Kulkarni JG. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology. 2006;31(4):543-547.

McElroy S. Short-and longer-term treatment with lurasidone in patients with bipolar I depression: Effect on metabolic syndrome. Neuropsychopharmacology. 2013;38:S535-S536.

McElroy SLW. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance." International Clinical Psychopharmacology. 2009;26(1):48-53.

Meyer TD, et al. The Hypomania Checklist-32 and the Mood Disorder Questionnaire as screening tools - Going beyond samples of purely mood-disordered patients. Journal of Affective Disorders. 2011;128(3):291-298.

Miklowitz DJ, Schneck CD, et al. Early intervention for symptomatic youth at risk for bipolar disorder: A randomized trial of family-focused therapy. Journal of the American Academy of Child and Adolescent Psychiatry. 2013;52(2):121-131.

Miller CJ, et al. Three studies on self-report scales to detect bipolar disorder. Journal of Affective Disorders. 2011;128(3):199-210.

Murphy BL, Stoll AL, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: A double-blind, randomized add-on clinical trial. Journal of Clinical Psychopharmacology. 2012;32(5):699-703.

Nierenberg AA, Friedman ES, et al. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. The American Journal of Psychiatry. 2013;170(1):102-110.

Nierenberg AA, Ostacher MJ, Calabrese JR. Treatment resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation

with lamotrigine, inositol or risperidone. American Journal of Psychiatry. 2006;163:210-216.

Nolen WAK. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study. Acta Psychiatrica Scandinavica. 2007;115(5): 360-365.

Norris ER, Karen B, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. Journal of Affective Disorders. 2013;144(1-2):141-147.

Okuma T, Inanaga K, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology. 1981;73(1): 95-96.

Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Journal of Clinical Psychiatry. 2005;66(6):726-9.

Papadakis AK, Starace A, Thomson L, Andor GY, Németh GY, Laszlovszky I. Phase II trial cariprazine in acute mania associated with bipolar I disorder: Effect across symptoms. 49th Annual New Research Approaches for Mental Health Interventions Meeting, 29 June -2 July 2009, Hollywood, Fl.

Pickett-Schenk SAL. Improving knowledge about mental illness through family-led education: The journey of hope. Psychiatric Services. 2008;59(1):49-56.

Praharaj SKR. Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: A randomized sham controlled study. Journal of Affective Disorders. 2009;117(3):146-150.

Prasko J, Latalova K, Cerna M, et al. Internet based psychoeducative CBT program for bipolar patients treated with thymostabilisers. European Psychiatry. 2013;28 (conference abstract).

Preti A, et al. The psychometric discriminative properties of the Peters et al Delusions Inventory: a receiver operating characteristic curve analysis. Comprehensive Psychiatry. 2007;48(1):62-69.

Sanchez-Moreno J, et al. Adaptation and validation of the Spanish version of the Mood Disorder Questionnaire for the detection of bipolar disorder. Bipolar Disorders. 2008;10(3): 400-412.

Schaffer LC, Schaffer CB, Miller AR, et al. An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. Journal of Affective Disorders. 2013;147:407-410

Sheehan DVM. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. Journal of Affective Disorders. 2009;115(3):376-385.

Sheehan DVK, Sheehan H, et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. Journal of Affective Disorders. 2013;145(1):83-94.

Singh V, Bowden CL, Mintz J. Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania. International Clinical Psychopharmacology. 2013;28:91-5.

Smith AH, et al. Placebo-controlled double-blind trial of mianserin hydrochloride. British Journal of Clinical Pharmacology. 1978;5(1):67S-70S

Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. Journal of Clinical Psychiatry. 1997;58:95–9.

Speer AMB. Opposite effects of high and low frequency rTMS on mood in depressed patients: Relationship to baseline cerebral activity on PET. Journal of Affective Disorders. 2009;115(3):386-394.

Stamm TA. Supraphysiological doses of levothyroxine in bipolar depression: A randomised controlled, double blind study. European Neuropsychopharmacology. 2011; Conference abstract (var.pagings).

Staring ABPV. Treatment adherence therapy in people with psychotic disorders: Randomised controlled trial. British Journal of Psychiatry. 2010;197(6):448-455.

Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 Fatty Acids in Bipolar Disorder. Archives of General Psychiatry 1999;56 (5):407–12.

Suppes T, Webb A, Paul B, Carmody T, et al. Clinical outcome in a randomised 1-year trial of clozapine versus treatment as usual for patients with treatment-resistent illness and a history of mania. American Journal of Psychiatry. 1999;156:1164-1169.

Szuba MPA. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression." Journal of Clinical Psychopharmacology. 2005;25(4):325-330.

Tamayo JM. Effectiveness and safety of the combination of fluoxentine and olanzapine in outpatients with bipolar depression: An open-label, randomized, flexible-dose study in Puerto Rico. Journal of Clinical Psychopharmacology. 2009;29(4).

Tohen MC. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry. 2006;163(2):247-256.

Vieta, E, et al. Cross validation with the mood disorder questionnaire (MDQ) of an instrument for the detection of hypomania in Spanish: The 32 item hypomania symptom check list (HCL-32). Journal of Affective Disorders. 2007;101(1-3):43-55.

Vita A, De Peri L, Siracusano A, Sacchetti E. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: Meta-analyses of randomized-controlled trials. International Clinical Psychopharmacology. 2013;28(5):219-227.

Wang ZG. Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: A 12-week, double-blind, placebo-controlled pilot study. Psychopharmacology bulletin. 2010;43(4):5-21.

Watson S, Gallagher P, et al. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biological Psychiatry. 2012; 72(11):943-9.

Woo YSB. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar i disorder: A 6-month, randomized, placebo-controlled, doubleblind maintenance trial. Human Psychopharmacology. 2011;26(8):543-553.

Wozniak JM. (unpublished) Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents [NCT00592683]. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00592683 [accessed 5 March 2014].

Wozniak JM. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology. 2009;19(5):539-545.

Yang FDL. Optimized therapeutic scheme and individualized dosage of sodium valproate in patients with bipolar disorder sub-type I. Chinese Journal of New Drugs. 2009;18(1):47-52.

Yong Ning Z and Z Hui. Therapeutic Effect of Mirtazapine Combined with Lithium Carbonate on Bipolar Depression. Chinese Mental Health Journal. 2005;19:492-494.

Young AH, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29(8):1538-1545.

Young R, et al. A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry. 1978;133:429-435.

Youngstrom EA, et al. Toward an integration of parent and clinician report on the Young Mania Rating Scale. Journal of Affective Disorders. 2003;77(2):179-190.

Youngstrom EA, et al. Comparing the diagnostic accuracy of six potential screening instruments for bipolar disorder in youths aged 5 to 17 years. Journal of the American Academy of Child & Adolescent Psychiatry. 2004;43(7):847-858.

Youngstrom EA, et al. Comparing diagnostic checklists for pediatric bipolar disorder in academic and community mental health settings. Bipolar Disorders. 2005;7(6):507-517.

Youngstrom EA, et al. Can we detect bipolar in youths? Diagnostic efficiency of caregiver, youth, and teacher report of manic symptoms in outpatient settings. Neuropsychopharmacology, 2011;36:S420-S421.

Zarate CAJ. Double-Blind Comparison of the Continued Use of Antipsychotic Treatment Versus Its Discontinuation in Remitted Manic Patients. American Journal of Psychiatry. 2004;161(1):169-171.

Zhang ZJ, Kang WH, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. Journal of Psychiatric Research. 2007;41(3-4):360-9.

Zimmerman M, et al. Detecting differences in diagnostic assessment of bipolar disorder. Journal of Nervous and Mental Disease. 2010;198(5):339-342.